Pfizer Inc. (NYSE:PFE) Inks Licensing Deal with Repligen - LLY, JNJ, BMY

Pompano Beach, FL -- (SBWIRE) -- 01/04/2013 -- Pfizer Inc. (NYSE:PFE) has licensed the privileges to a biologic research program that tries to expand new treatments for the muscle wasting circumstance spinal muscular atrophy (SMA).

How Should Investors Trade PFE Now? Don’t Miss out a Special Trend Analysis

Even though the agreement could be valued up to $70 million to Repligen headquartered on milestone expenditure, Pfizer has been watchful in its upfront imbursement, and the US company will firstly get just $5 million.

The key candidate concerned in the program is RG3039, which will go through phase I trials performed by Repligen in the Q1 of 2013.

Once these have been finished, Pfizer will then assume complete responsibility for the SMA program, which as well comprises backup compounds and allowing technologies.

So far today, Pfizer Inc. (NYSE:PFE) shares increased +0.43% to $25.96 while the stock is changing hands within a range of $25.81 – $25.98. In the past year, the stock has traded between $20.75 and $26.09. Its average daily trading volume is 30.33 million shares.

What was the Moving Force behind PFE On Bullish Run? Read This Research Report

Looking at other stocks within industry, Eli Lilly & Co, Johnson & Johnson and Bristol Myers Squibb Co were in the gainers list. Let’s have a quick look on their Market performance.

Eli Lilly & Co. (NYSE:LLY) shares are up +3.96% to $51.69 while the stock is trading within the range of $50.69 – $51.90 in the current trading session. In the last 12 months, shares have floated between $38.30 and $53.99. This stock, on average, has trading volume of 6.37 million shares.

For How Long LLY will Fight for Profitability? Read This Trend Analysis report

In this session so far, Johnson & Johnson (NYSE:JNJ) shares moved up +1.20% reaching $71.59. The stock is trading in a range of $71.01 – $71.73. In the last year the stock has moved within a range of $61.71 – $72.74. The Company’s average daily trading volume is 11.00 million shares.

Will JNJ Continue To Move Higher? Find Out Here

Another rival company, Bristol Myers Squibb Co. (NYSE:BMY), is trending +0.12% higher to $33.28. The stock price is hovering in range of $33.20 to $33.40. In the previous 52 weeks, shares price ranged between $30.64 and $36.34. Their average daily trading volume is 8.06 million shares.

Why Should Investors Buy BMY After The Recent Gain? Just Go Here and Find Out

About TopStockPlays
The TopStockPlays.com expert team is highly experienced in picking the low-priced shares with the biggest profit potential. We uncover the hidden gems in the stock market-shares that can break out for gains of 300%, 400%, even 500% within a few weeks.

Disclaimer
PLEASE NOTE WELL: The TopStockPlays.com employees are not registered as an Investment Adviser in any jurisdiction whatsoever. Please do your research or consults your financial adviser before making any Investment decision. TopStockPlays.com or its employees will not be responsible for any loss or losses.